{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:52:41Z","timestamp":1789588361462,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2025.106051","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:51:14Z","timestamp":1769500274000},"page":"106051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Planchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Grouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Le Reun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Luttenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boussahoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-1584","authenticated-orcid":false,"given":"B.","family":"Macabeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.106051_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.106051_bib2","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib3","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/j.jtho.2020.07.007","article-title":"Durable response to dabrafenib combined with trametinib in a patient with NSCLC harboring a BRAF G469A mutation","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103008","article-title":"A BRAF new world","volume":"152","author":"Frisone","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2025.106051_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tlcr.2019.10.22","article-title":"Targeting BRAF mutations in non-small cell lung cancer","volume":"8","author":"O\u2019Leary","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106051_bib20","series-title":"ESMO oncogene-addicted metastatic non-small-cell lung cancer living guideline, v1.2 - January 2025","year":"2025"},{"key":"10.1016\/j.esmoop.2025.106051_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.106051_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.106051_bib14","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib15","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC\u2014a brief report","volume":"20","author":"Riely","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.106051_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2025.106051_bib23","author":"Dias"},{"key":"10.1016\/j.esmoop.2025.106051_bib24","author":"Phillippo"},{"key":"10.1016\/j.esmoop.2025.106051_bib25","series-title":"Cochrane handbook for systematic reviews of interventions, version 6.3","author":"Higgins","year":"2022"},{"key":"10.1016\/j.esmoop.2025.106051_bib28","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.esmoop.2025.106051_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2025.106051_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.106051_bib31","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1316","article-title":"1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): an open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)","author":"Planchard","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:51:53Z","timestamp":1773975113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702925019210"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106051","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106051"}}